Therabron Therapeutics is a clinical-stage biotechnology company based in Rockville, MD, focused on respiratory care and disease-modifying therapeutics. Its lead biologic candidate, CG100, is a recombinant secretoglobin being investigated in a Phase 2 clinical trial to prevent chronic respiratory morbidities in preterm infants. The company is advancing other programs with the goal of opening a second IND in 2016 targeting PICU patients at risk of respiratory failure from pathogens such as influenza and RSV. Additional lead optimization activities will progress for analogues of recombinant human CC10 proteins intended to target ambulatory respiratory disorders such as COPD. Founded in 2007 and led by President Dr. Thomas F. Miller, Therabron is developing a broader recombinant secretoglobin platform beyond CG100. Financially, it received a second tranche of its previously announced Series B financing, securing gross proceeds of up to $6.75M to support ongoing development. Therabron Therapeutics is a clinical-stage biotechnology company developing synthetic human CC10 proteins (rhCC10) to restore immune balance in the lungs and treat respiratory diseases. Its lead program, CG100 (rhCC10), is a recombinant version of the native CC10 protein, a potent anti-inflammatory factor deficient in many respiratory diseases. RhCC10 has completed two Phase 1 trials showing safety, potent anti-inflammatory activity, and significant long-term benefit in premature infants; it has Orphan Drug designation to prevent bronchopulmonary dysplasia (BPD). The ongoing Phase 2 randomized trial of CG100 in very premature infants is over 30% enrolled and aims to enroll 88 infants, with enrollment projected to take another 12 months. Therabron plans to initiate a second trial for its CG201 candidate in 2015, conduct a clinical trial in COPD, and advance several preclinical compounds into Phase 1 studies. Funding from the Series B will support further clinical development of rhCC10 and these planned programs.

Total raised

$18M

Funding rounds

2

Latest round

Series B

Latest activity

Nov 2015